Researchers at the University of Copenhagen have identified the protein NDRG1 as a potential therapeutic target for cancer, utilizing the antimalarial drug quinacrine to exploit specific cellular vulnerabilities. According to a study published in Science Signaling, high levels of NDRG1 correlate with poor patient survival, and inhibiting this protein creates a synthetic lethal interaction that forces cancer cells to die while potentially sparing healthy tissue.
The Mechanism of Synthetic Lethality in Oncology
The research team, led by Assistant Professor Garik V. Mkrtchyan, utilized the concept of synthetic lethality to uncover new ways to treat malignancy. This approach relies on the biological fact that cancer cells often harbor mutations in DNA damage response pathways, leaving them dependent on remaining repair mechanisms to survive.
By inhibiting a second, necessary gene or protein—in this case, NDRG1—scientists can trigger the death of cancer cells that have already lost other vital repair functions. This is a strategy currently used in the treatment of ovarian, breast, and prostate cancers that feature BRCA mutations, which are targeted by PARP inhibitors.
Did you know?
Quinacrine has been used medically for nearly a century. Originally developed as an antimalarial drug, it was later approved for the treatment of lupus before researchers began investigating its potential in precision oncology.
Identifying Drug Sensitivity Through Robotics
To determine which cancers might respond to this approach, the team employed automated robotics to screen more than 130 different cancer cell lines. The findings, published in Science Signaling, indicated that blood cancers often exhibit high NDRG1 expression and are particularly sensitive to quinacrine.
The study also highlighted colorectal cancer cells as a target, specifically those with mutations in the MLH1 and PARP3 genes. When researchers analyzed patient datasets, they confirmed that patients with high NDRG1 expression combined with the loss of these specific genes showed improved survival rates.
Future Directions for Precision Oncology
While quinacrine shows promise, the research team is already looking toward the next phase of development. Because the drug can cause unwanted side effects, the goal is to create more potent and specific small-molecule inhibitors of NDRG1.
“The next steps will be to develop small molecules that inhibit NDRG1 with greater potency and specificity than quinacrine, thereby minimizing potential off-target effects,” Mkrtchyan stated. The team intends to validate these synthetic lethal interactions in preclinical tumor models to determine if targeting the NDRG1 axis can help overcome treatment resistance in a wider variety of cancer types.
Pro Tip: Biomarkers in Treatment
The study suggests that NDRG1 expression levels could eventually be used as a clinical biomarker. Identifying patients with high NDRG1 expression may help clinicians select those most likely to benefit from therapies that specifically target this DNA damage response pathway.
Frequently Asked Questions
What is synthetic lethality?
Synthetic lethality occurs when the loss of one of two genes allows a cell to survive, but the loss of both genes simultaneously causes the cell to die. Cancer treatments use this to target specific vulnerabilities in tumor cells.
Why is NDRG1 significant in cancer treatment?
According to the University of Copenhagen study, high NDRG1 expression is linked to poor survival outcomes. Inhibiting this protein exploits a vulnerability in the cancer cell’s DNA damage response, offering a potential path for precision therapy.
Is quinacrine currently used to treat cancer?
While quinacrine has shown anticancer activity in laboratory settings, it is not a standard cancer treatment. Researchers are currently using it as a starting point to develop more specific, less toxic drugs that target the same biological pathways.
Are you interested in the latest developments in precision medicine? Subscribe to our newsletter for updates on emerging cancer research and clinical trial breakthroughs.
Related reading